Stada 2012 core profit up 45 pct, less than expected

FRANKFURT Thu Feb 28, 2013 7:41am EST

Related Topics

FRANKFURT Feb 28 (Reuters) - Stada Arzneimittel, Germany's largest independent generic drugmaker, posted 2012 core earnings slightly below expectations.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 45 percent to 323.8 million euros ($424.5 million) in 2012, Stada said on Thursday, citing preliminary figures.

That was less than the 357.1 million euros expected on average by analysts, based on Thomson Reuters I/B/E/S data.

The group also confirmed its 2014 targets. ($1 = 0.7628 euros) (Reporting by Ludwig Burger)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.